Want to see JP:9267 full AI Analyst Report?
Genky DrugStores Co., Ltd. (9267) AI Stock Analysis
Top Page
Genky DrugStores Co., Ltd.
(TSE/TYO:9267)
The score is driven primarily by solid financial performance (steady growth, stable profitability, and improved leverage) but is held back by inconsistent free cash flow. Technical signals are neutral-to-weak (below key moving averages and negative MACD), while valuation is supportive with a moderate P/E but minimal dividend yield.
Genky DrugStores Co., Ltd. (9267) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 103.59B
- Dividend Yield
- 0.38%
- Average Volume (3M)
- 71.42K
- Price to Earnings (P/E)
- 13.1
- Beta (1Y)
- 0.67
- Revenue Growth
- 8.38%
- EPS Growth
- 2.29%
- Country
- Japan
- Employees
- 6,291
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Genky DrugStores Co., Ltd. Business Overview & Revenue Model
Company Description
Genky DrugStores Co., Ltd. engages in the management and operation of food and drug chain stores in Japan. Genky DrugStores Co., Ltd. was founded in 1988 and is headquartered in Sakai, Japan.
Genky DrugStores Co., Ltd. Financial Statement Overview
Summary
Fundamentals are solid overall: steady revenue growth and stable (but thin) margins, plus improving leverage and consistent ROE. The main offset is cash-flow quality—free cash flow has been volatile and often negative despite improved operating cash flow, which reduces financial flexibility.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
56Neutral| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.64B | 220.64B | 200.79B | 184.86B | 169.06B | 154.64B |
| Gross Profit | 44.92B | 44.92B | 35.09B | 32.53B | 29.90B | 26.68B |
| EBITDA | 18.47B | 18.12B | 16.41B | 14.47B | 11.73B | 10.73B |
| Net Income | 7.88B | 7.88B | 7.07B | 6.32B | 4.76B | 4.42B |
Balance Sheet | ||||||
| Total Assets | 145.60B | 145.60B | 128.27B | 114.84B | 106.92B | 97.64B |
| Cash, Cash Equivalents and Short-Term Investments | 7.87B | 7.87B | 6.22B | 5.90B | 5.33B | 5.44B |
| Total Debt | 39.64B | 39.64B | 34.37B | 30.65B | 32.35B | 30.96B |
| Total Liabilities | 84.22B | 84.22B | 74.84B | 68.15B | 66.23B | 61.40B |
| Stockholders Equity | 61.37B | 61.37B | 53.43B | 46.68B | 40.68B | 36.23B |
Cash Flow | ||||||
| Free Cash Flow | -2.31B | -3.13B | -2.50B | 2.98B | -1.12B | -4.39B |
| Operating Cash Flow | 7.46B | 16.98B | 12.60B | 13.26B | 8.77B | 6.08B |
| Investing Cash Flow | -9.81B | -20.28B | -15.62B | -10.63B | -9.74B | -10.59B |
| Financing Cash Flow | 828.00M | 4.95B | 3.35B | -2.06B | 854.00M | 2.04B |
Genky DrugStores Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Negative. The current price of 3395.00 is below the 20-day moving average (MA) of 3408.25, below the 50-day MA of 3497.00, and below the 200-day MA of 3795.63, indicating a bearish trend. The MACD of -33.47 indicates Negative momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 36.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9267.
Genky DrugStores Co., Ltd. Peers Comparison
Overall Rating
JP:764969Neutral
JP:998969Neutral- JP:926764Neutral
JP:334959.9Neutral
JP:354956Neutral
JP:339154Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7649 | 69Neutral | JPY 506.97B | 16.12 | 9.94% | 1.34% | 8.97% | -29.54% |
| JP:9989 | 69Neutral | JPY 422.80B | 13.44 | 11.15% | 3.65% | 4.32% | 0.18% |
| JP:9267 | 64Neutral | JPY 104.38B | 13.13 | ― | 0.38% | 8.38% | 2.29% |
| JP:3349 | 60Neutral | JPY 480.15B | 14.88 | ― | 1.36% | 8.99% | 3.61% |
| JP:3549 | 56Neutral | JPY 418.12B | 21.94 | ― | 0.34% | 12.54% | 15.87% |
| JP:3391 | 54Neutral | JPY 1.01T | 17.51 | 7.13% | 2.10% | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:9267 | Genky DrugStores Co., Ltd. | 3395.00 | -1718.70 | -33.61% | |
| JP:9989 | Sundrug Co | 3616.00 | -399.89 | -9.96% | |
| JP:7649 | Sugi Holdings Co | 1304.50 | -340.92 | -20.72% | |
| JP:3391 | TSURUHA Holdings | 2236.00 | -391.62 | -14.90% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6032.00 | -789.24 | -11.57% | |
| JP:3549 | KUSURI NO AOKI HOLDINGS CO.,LTD. | 4373.00 | 523.54 | 13.60% |
Genky DrugStores Co., Ltd. Corporate Events
Genky DrugStores Extends Store Expansion as Tax Changes Temper Profit Outlook
Genky DrugStores reported continued expansion for the fiscal year ended June 2027, with revenue rising to ¥220.6 billion and net income increasing to ¥7.88 billion. Store count grew to 604 locations and average sales per tsubo climbed, lift...
Genky DrugStores Sales Rise but Profits Dip; FY2027 Outlook Stays Positive
Genky DrugStores reported net sales of ¥59.5 billion for the three months ended September 20, 2026, up 6.2% year-on-year, but operating and ordinary income declined 5.3% and 7.4% respectively, with net income attributable to owners of the parent...
Genky DrugStores grows sales and store network while standardizing formats
Genky DrugStores reported continued year-on-year growth in net sales across all stores in October for the fiscal year ending June 2027, with sales up 6.8% and total store count rising to 543. Existing-store sales were slightly weaker, reflecting lowe...
Genky DrugStores Finalizes New Equity-Based Stock Option Plan for Executives and Staff
Genky DrugStores Co., Ltd., a Japanese drugstore and pharmacy retailer listed on the TSE Prime, sells pharmaceuticals and daily goods to domestic consumers through its main operating company and subsidiaries. Its governance framework centers on board...
Genky DrugStores Sustains Sales Growth on Store Expansion and Standardization
Genky DrugStores reported steady growth in all-store net sales for the latest months, with year-on-year gains generally above 6%, supported by rising customer traffic despite slightly weaker spending per customer at existing stores. Existing-store sa...
Genky DrugStores Expands Stock Option Eligibility Without Increasing Issuance
Genky DrugStores Co., Ltd. operates in Japan’s drugstore and pharmacy retail industry, offering pharmaceuticals, daily necessities, and health-related products through its Genky-branded stores and subsidiaries. The company is listed on the Toky...
Genky DrugStores Grants Stock Options to Align Management with Performance
Genky DrugStores Co., Ltd., a Prime Market-listed Japanese drugstore operator, sells pharmaceuticals and daily goods through its Genky Stores chain and aims to expand its consolidated business performance. The company’s management structure spa...
Genky DrugStores Grows Sales on Store Expansion Despite Same-Store Softness
Genky DrugStores reported August net sales for all stores up 6.5% year on year, with existing-store sales slightly down 0.7% amid higher customer traffic but lower spending per customer. The chain continued its expansion and standardization drive, op...
Genky DrugStores Plans Stock Options to Align Management and Employee Incentives
Genky DrugStores has proposed issuing stock acquisition rights as stock options on favorable terms to internal directors and employees, as well as directors and employees of its subsidiaries, subject to approval at its upcoming annual general meeting...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026